Treatment of obesity: an update on anti‐obesity medications

Halpern, Alfredo; Mancini, Márcio C.

doi:10.1046/j.1467-789x.2003.00083.x

Cited by 103 publications

(68 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At present, only two drugs are approved for the long-term treatment of overweight patientsFsibutramine and orlistat. 4,5 Appetite-suppressant drugs, by reducing overall hunger sensation, can help obese patients diminish weight. 6 Despite apparent differences in pharmacology and abuse potential, there is still a tendency to refer to all centrally acting sympathomimetic appetite suppressants as 'amphetaminelike' and to view them all with equal harm potential.…”

Section: Introductionmentioning

confidence: 99%

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects

et al. 2009

View full text Add to dashboard Cite

Objective: To evaluate the efficacy of diethylpropion on a long-term basis, with emphasis in cardiovascular and psychiatric safety aspects. Design: Randomized, double-blind, placebo-controlled trial Measurements: Following a 2-week screening period, 69 obese healthy adults received a hypocaloric diet and were randomized to diethylpropion 50 mg BID (n ¼ 37) or placebo (n ¼ 32) for 6 months. After this period, all participants received diethylpropion in an open-label extension for an additional 6 months. The primary outcome was percentage change in body weight. Electrocardiogram (ECG), echocardiography and clinical chemistry were performed at baseline and every 6 months. Psychiatric evaluation and application of Hamilton rating scales for depression and anxiety were also performed by experienced psychiatrists at baseline and every 3 months. Results: After 6 months, the diethylpropion group lost an average of 9.8% (s.d. 6.9%) of initial body weight vs 3.2% (3.7%) in the placebo group (Po0.0001). From baseline to month 12, the mean weight loss produced by diethylpropion was 10.6% (8.3%). Participants in the placebo group who were switched to diethylpropion after 6 months lost an average of 7.0% (7.7%) of initial body weight. The difference between groups at month 12 was not significant (P ¼ 0.07). No differences in blood pressure, pulse rate, ECG and psychiatric evaluation were observed. Dry mouth and insomnia were the most frequent adverse events. Conclusion: Diethylpropion plus diet produced sustained and clinically significant weight loss over 1 year. It seems to be safe in relation to cardiovascular and psychiatric aspects in a well-selected population.

show abstract

Section: Introductionmentioning

confidence: 99%

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects

et al. 2009

View full text Add to dashboard Cite

show abstract

“…[12][13][14][15][16][17][18][19] A good recent metaanalysis about pharmacologic treatment of obesity could not present pooled analyses of fluoxetine treatment, because the statistical tests and Forest plot of individual study results revealed too much heterogeneity. However, in six of the seven studies, significant weight loss has been observed as being controlled by placebo.…”

Section: Obesity Treatment By Metformin-fluoxetine M Siavash Dastjerdmentioning

confidence: 99%

“…15 By blocking the membrane-uptake carrier that transports serotonin from the extracellular space to inside the serotonin nerve terminals, fluoxetine increases extracellular concentrations of serotonin and amplifies signals sent by serotonin neurons. Because serotonin neurons are widespread in the central nervous system, the functional consequences of blocking serotonin uptake are diverse; this includes symptoms such as decreased food intake, altered food selection and endocrine changes.…”

Section: Obesity Treatment By Metformin-fluoxetine M Siavash Dastjerdmentioning

confidence: 99%

An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction

et al. 2006

View full text Add to dashboard Cite

Background: Obesity is a very important risk factor for cardiovascular disease, type 2 diabetes mellitus, hypertension, osteoarthritis, fatty liver, metabolic syndrome and respiratory problems. Many weight-reducing drugs cannot be used in obese patients because of numerous complications. Fluoxetine, an antidepressant, and metformin, an antidiabetic drug, reduce weight as their side effect, but the potency of each drug is not always enough. Here, we studied the effects of combination therapy of them for weight reduction in obese women. Materials and methods: This study was designed as an open, prospective, controlled clinical trial. Obese and overweight patients referred to obesity clinics were first put under a diet and behavior therapy education program before being invited to this study. The patients who accepted drug therapy were put in the case group. Those who did not accept drug therapy were put in the control group. Fluoxetine, 20 mg daily, and metformin, 500 mg three times daily, were prescribed to the participants. Weight and body mass index (BMI) changes within case and control groups were analyzed by paired t-tests and between groups by t-testing. Side effects were evaluated by interview and questionnaire. Subjects: Two hundred and three patients were referred to obesity clinics. Of these, 177 were female with 91 being volunteers for this study. Of this 91, 66 were in the case group and 25 in the control group. Results: In a 6.68-month period, a 7.89 kg decrease in weight (9.32%) and a 3.43 U decrease in BMI (10.14%) were observed in participants of the case group that was statistically significant (Po0.0001). The participants of the control group were followed for a mean period of 8.12 months. In this period, the participants of the control group showed a 0.48 kg decrease in weight (0.52%) and a 0.11 U decrease in BMI (0.42%). This was not significant. No serious side effects of the drugs were observed in the case group.Conclusion: This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo.

show abstract

“…Vários trabalhos demonstram que até 70% de uma dose de femproporex pode se biotransformar no organismo, em anfetamina livre (Cody, 2002;Kraemer, Maurer, 2002;Musshoff, 2000;Cody, Valtier, 1999;Cody, Valtier, 1996;Sznelwar, 1975). Apesar disso e de ser controlado por legislação específica (Brasil, 1997), vários trabalhos demonstram que este fármaco tem sido amplamente utilizado, não somente como inibidor do apetite (Halpern, Mancini, 2003;Rodrigues et al, 2002), mas também como estimulante da vigília (INCB, 1998;Silva et al, 1998;Lopes et al, 1997;Nappo, Oliveira, Morosini, 1994;Nappo, 1992).…”

Section: Introductionunclassified

Identificação de anfetamina em amostras de cabelo por imunofluorescência polarizada

Mariz¹,

Silva²

2003

Rev. Bras. Cienc. Farm.

View full text Add to dashboard Cite

Treatment of obesity: an update on anti‐obesity medications

Cited by 103 publications

References 127 publications

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects

An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction

Identificação de anfetamina em amostras de cabelo por imunofluorescência polarizada

Contact Info

Product

Resources

About